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Abstract Here we report that the L-adrenergic agonist
isoproterenol increases the activity of the stress-activated kinase
p38 MAPK over 10-fold in freshly isolated rat epididymal fat
cells. Stimulation of the kinase was rapid, sustained for at least
60 min and sensitive to the specific p38 MAPK inhibitor, SB
203580. Half-maximal stimulation of p38 MAPK by isoproter-
enol occurred at 13 nM isoproterenol. The cell permeable cyclic
AMP analogue, chlorophenylthio-cyclic AMP increased p38
MAPK activity to a similar extent to isoproterenol, suggesting
that the effect of the L-adrenergic agonist is mediated via
increases in the activity of cyclic-AMP dependent protein kinase.
Although it had little or no effect on the activity of c-Jun N-
terminal kinase, isoproterenol and a number of other treatments
which activated p38 MAPK were found to stimulate AMP-
activated protein kinase in fat cells. Activation of AMPK and
p38 MAPK were not, however, found to be directly linked.
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1. Introduction
Mammalian cells respond to environmental stresses such as
UV irradiation and osmotic and heat shock by activating
protein kinase cascades that give rise to stimulation of the
c-Jun N-terminal kinases (JNK/SAPK1s) and p38 mitogen
activated protein kinase (MAPK) (also known as SAPK2
and RK). These stress activated protein kinases also respond
to in£ammatory cytokines such as interleukin-1 and tumour
necrosis factor-K (for review see [1]). Activation of JNK fam-
ily members gives rise to increased transcription via direct
phosphorylation of transcription factors such as c-Jun and
ATF2 (see [2]). While p38 MAPK also phosphorylates a num-
ber of transcription factors including CHOP [3] and ATF2 [4],
it has also been shown to phosphorylate and activate the
kinases MAPKAP-K2 [5^7], MAPKAP-K3 [8] and MAPK
interacting kinase (Mnk1) [9]. Increases in MAPKAP-K2 ac-
tivity give rise to phosphorylation of cyclic AMP-response-
element binding protein (CREB) [7,10] and heat shock protein
27 (HSP27) [10,11], while Mnk1 has been shown to phosphor-
ylate the eukaryotic initiation factor 4E [9]. A number of
other substrates for p38 MAPK have also been inferred by
use of two speci¢c p38 MAPK inhibitors, SB 203580 and SB
202190 (see [2]).
Recently p38 MAPK has been shown to be activated by
agonists signalling through a number of di¡erent G protein-
coupled receptors, including the L-adrenergic Gs-coupled re-
ceptor in human embryonic kidney 293 cells [12]. L-Adrener-
gic agonists were classically thought to bring about their ef-
fects via activation of adenylate cyclase by GKs, and hence by
increases in the intracellular levels of cyclic AMP. More re-
cently, much work has focussed on the additional role of GLQ
subunits in signalling through heterotrimeric G proteins (see
[13] for a review). The mechanism by which the L-adrenergic
agonist isoproterenol brings about its metabolic e¡ects in fat
cells is thought to be largely through GKs activation of adenyl
cyclase, although we have recently reported that it stimulates
the activity of protein kinase B via a cAMP-independent
mechanism [14]. In order to further investigate the signalling
pathways activated by isoproterenol in these cells we have
determined its e¡ect on the stress-activated protein kinases.
In this paper we demonstrate that isoproterenol stimulates
the activity of p38 MAPK in fat cells, and that this activation
appears to be brought about via increases in cyclic AMP.
Under the conditions used here, we have also shown that
isoproterenol stimulates the AMP-activated protein kinase
(AMPK), a kinase that is activated in response to metabolic
stress. The e¡ect of isoproterenol on the activity of p38
MAPK, however, occurs independently of any changes in
AMPK activity.
2. Materials and methods
2.1. Materials
Rabbit polyclonal antibodies against p38 MAPK and JNK, and the
substrate proteins GST-Jun and GST-ATF2 [4] were kindly donated
by Dr Martin Dickens, University of Leicester, UK. The sheep poly-
clonal serum raised against AMPK (reactive against both the K1 and
K2 isoforms of the catalytic subunit of AMPK) was the generous gift
of Dr David Carling, Royal Postgraduate Medical School, Hammer-
smith Hospital, London, UK. All other materials were as in [14].
2.2. Preparation and incubation of epididymal fat cells
Adipocytes were isolated from the epididymal fat pads of Wistar
rats (175^200 g) and incubated as described previously [15]. Cells
(150^250 mg dry cell weight) were extracted in 1 ml of ice cold 50
mM HEPES (pH 7.6), 0.2 mM EDTA, 2.2 mM EGTA, 1 mM dithio-
threitol, 100 mM KCl, 10% glycerol, 1% Triton X-100, 1 WM micro-
cystin and 1 Wg/ml each of pepstatin, leupeptin and antipain. Extracts
were centrifuged at 10 000Ug for 10 min at 4‡C prior to use, and the
infranatant taken for the measurement of protein kinase activity.
2.3. Assays of p38 MAPK and JNK
p38 MAPK was immunoprecipitated from cell extracts using a
1:200 dilution of anti-p38 MAPK serum plus 5 mg protein A-Sephar-
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ose. Immunoprecipitates were washed twice and then resuspended in
10 Wl assay bu¡er (20 mM HEPES, pH 7.5, 20 mM L-glycerophos-
phate, 1 mM EDTA, 1 mM dithiothreitol, 200 WM cyclic AMP-de-
pendent protein kinase inhibitor peptide IP20). The activity of p38
MAPK in immunoprecipitates was assessed using GST-ATF2 (12.5
Wg) as a substrate for 15 min at 30‡C in the presence of 2 mM MgCl2
and [Q-32P]ATP (100 WM, 200^500 cpm/pmol). JNK activity was sim-
ilarly assessed in anti-JNK immunoprecipitates using GST-Jun as a
substrate. Phosphorylated GST-ATF2 and GST-Jun were run on
SDS-PAGE and the degree of phosphorylation was quanti¢ed after
radioautography by densitometric scanning.
2.4. AMPK assays
For the determination of AMPK activity, fat cells were snap frozen
in liquid nitrogen prior to extraction in ice-cold 0.25 M mannitol,
50 mM Tris-HCl (pH 7.2), 1 mM EDTA, 50 mM NaF, 5 mM sodium
pyrophosphate, 1 mM benzamidine, 1 mM dithiothreitol and 1 Wg/ml
pepstatin, leupeptin and antipain. Extracts were prepared as above
and AMPK immunoprecipitated using 2 Wl anti-AMPK antiserum
plus 10 Wl 50% protein G slurry per ml of cell extract. Immunopreci-
pitates were washed three times with, and ¢nally resuspended in,
AMPK assay bu¡er (40 mM HEPES (pH 7.0), 80 mM NaCl, 8%
(v/v) glycerol, 0.8 mM EDTA, 2 mM MgCl2, 200 WM IP20, 1 mM
dithiothreitol). Kinase activity was measured in the presence of
[Q-32P]ATP (100 WM, 500^1000 cpm/pmol), 200 WM AMP and
200 WM SAMS peptide for 15 min at 30‡C [16].
3. Results
To characterise the response to stress in rat epididymal fat
cells the activities of both p38 MAPK and JNK were assessed
under a variety of conditions (Fig. 1). The activity of p38
MAPK was increased 10.68 þ 0.84 fold (n = 5 separate cell
preparations) by the L-adrenergic agonist isoproterenol. Sim-
ilar levels of activation were also seen with the L3-adrenergic
receptor-speci¢c agonist BRL 37344 and adrenalin (results not
shown). The cytokine-suppressive anti-in£ammatory drug SB
203580, a speci¢c p38 MAPK inhibitor [2], largely ablated the
e¡ect of isoproterenol (Fig. 1A), indicating that the SB
203580-sensitive K- and L-isoforms of p38 MAPK may be
the predominant isoforms a¡ected by isoproterenol in fat
cells. Arsenite and hyperosmolarity also potently activated
p38 MAPK. Some degree of activation of the kinase was
also seen in response to the protein synthesis inhibitor aniso-
mycin. Isoproterenol had little or no e¡ect on the other main
stress-activated kinase, JNK, although this was strongly acti-
vated by both arsenite and hyperosmolarity (Fig. 1B). Aniso-
mycin had no e¡ect on JNK activity.
In order to investigate the mechanism by which isoproter-
enol increased the activity of p38 MAPK, the e¡ect of the cell
permeable, non-metabolisable cyclic AMP analogue cpt-
cAMP was measured. Cpt-cAMP activated p38 MAPK
4.04 þ 0.64-fold (n = 4 separate cell preparations) (Fig. 1C),
indicating that increased activity of cAMP-dependent protein
kinase may underlie the e¡ect of L-adrenergic agonists on p38
MAPK. Activation of phosphatidylinositol 3-kinase does not
seem to be involved in the e¡ect of isoproterenol as pretreat-
ment with the inhibitor wortmannin did not inhibit the stim-
ulation of p38 MAPK (data not shown). Insulin, which has
no signi¢cant e¡ect on p38 MAPK on its own, reversed the
stimulation of p38 MAPK caused by low doses (20 nM) of
isoproterenol (results not shown).
The time course for the activation of p38 MAPK by iso-
proterenol (Fig. 2) showed that activation of the kinase
peaked after 10^20 min incubation with the agonist, and
was sustained for at least 60 min. Over the times studied,
the activity of p38 MAPK did not alter signi¢cantly in un-
treated control cells. The dose response curve for the e¡ect of
isoproterenol (Fig. 3) shows that half maximal activation of
p38 MAPK occurred at 13 þ 3 nM isoproterenol (n = 3 sepa-
rate cell preparations). This EC50 for the activation of p38
MAPK was similar to that for the stimulatory e¡ects of iso-
proterenol on cyclic AMP-dependent protein kinase [17], li-
polysis [17] and glycogen breakdown [18].
In addition to studying the e¡ect of isoproterenol on ki-
nases that are involved in the response of cells to environ-
mental stress, we have also determined its e¡ect on a kinase
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Fig. 1. Activation of p38 MAPK and JNK in adipocytes. Adipo-
cytes were incubated with isoproterenol (Iso, 1 WM), anisomysin
(Ans, 10 Wg/ml), arsenite (Ars, 5 mM), sorbitol (Hyp, 0.5 M), cpt-
cAMP (Cpt, 5 mM) or with no additions (Con) for 10 min. Where
indicated, cells were preincubated for 30 min with 5.3 WM SB
203580. The activities of p38 MAPK (A and C) and Jnk (B) were
assessed in the same cell extracts as described in Section 2, and
phosphorylated GST-ATF2 and GST-Jun were visualised by radio-
autography. Results shown are representative of at least 3 separate
experiments.
Fig. 2. Time course for activation of p38 MAPK by isoproterenol.
Adipocytes were incubated for the times indicated in the presence of
1 WM isoproterenol. The activity of p38 MAPK was quanti¢ed as
described in Section 2. Results are expressed as percentage of con-
trol, unstimulated p38 MAPK activity at time 0 and are means
þ S.E.M. of three separate cell preparations.
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that is acutely sensitive to metabolic stress, namely the AMP-
dependent protein kinase. Under the conditions used to incu-
bate the adipocytes, isoproterenol increased the activity of
AMPK activity assayed in the presence of saturating concen-
trations of AMP (200 WM) over 2.5-fold (Fig. 4). It is there-
fore likely that the activation seen is a result of phosphoryla-
tion and activation of the AMPK in the cells prior to
extraction. Fig. 4 also shows that both hyperosmotic shock
and arsenite stimulated the AMPK approximately 4-fold in
fat cells. Insulin had no e¡ect on the activity of the kinase.
Treatment of adipocytes with the cell permeable compound
5-amino-4-imidazolecarboxamide ribonucleoside (AICAR)
has previously been shown to speci¢cally increase the activity
of AMPK [19,20]. AICAR is phosphorylated within the cells
to produce AICAR monophosphate (ZMP), which mimics the
e¡ect of AMP on AMPK. ZMP activates AMPK both allos-
terically, and by promoting its phosphorylation by the AMPK
kinase [20,21]. Incubating adipocytes with AICAR had no
e¡ect on the activity of p38 MAPK, indicating that the stim-
ulation of AMPK was not responsible for the observed in-
creases in p38 MAPK activity seen with isoproterenol, hyper-
osmotic shock or arsenite (Fig. 4, insert).
4. Discussion
This study shows that isoproterenol increases the activity of
the stress-activated protein kinase p38 MAPK in rat fat cells.
A number of other reports have also implicated G protein-
coupled receptor agonists in the control of p38 MAPK, in-
cluding f-Met-Leu-Phe in neutrophils [22], thrombin in plate-
lets [23,24], and K-adrenergic agonists in myocardial cells
[25,26]. Similarly, Yamauchi et al. [12] have reported that
activation of p38 MAPK can also occur in human embryonic
kidney 293 cells in response to stimulation of Gs-coupled L-
adrenergic receptors, as well as via Gq=11-coupled m1 and Gi-
coupled m2 muscarinic acetylcholine receptors. Their ¢ndings,
however, indicated that signalling may occur through GLQ
subunits. Isoproterenol has been reported to increase the ac-
tivity of p38 MAPK in regenerating rat liver, and here the use
of a cAMP-dependent protein kinase inhibitor argued against
a role for cAMP in this process [27]. In contrast, our present
data indicate that p38 MAPK can be activated in fat cells
through increases in the intracellular concentration of
cAMP, and thus probably through changes in the activity of
cAMP-dependent protein kinase.
In fat cells the e¡ect of isoproterenol on MAPK signalling
pathways appears to be speci¢c for p38 MAPK, with neither
the JNK (this paper), nor the classical ERK signalling path-
ways being activated by L-adrenergic agonists [15]. Indeed,
activation of cAMP-dependent protein kinase through GKs-
mediated signalling has been shown to suppress activation of
ERK1/2 in this cell type [28].
We have previously shown that isoproterenol increases the
activity of PKB in adipocytes in a wortmannin-insensitive and
cAMP-independent manner [14], and the present studies were
initiated in an attempt to de¢ne potential signalling pathways
involved in this e¡ect. Protein kinase B has been shown to be
activated by cellular stress in other cell types [29]. However,
the involvement of cAMP in the activation of p38 MAPK
suggests that activation of this stress kinase does not underlie
the stimulation of protein kinase B by isoproterenol. In addi-
tion, we have been unable to show activation of protein ki-
nase B upon treatment of fat cells with other agents that
activate p38 MAPK, such as arsenite and hyperosmotic shock
(unpublished observations).
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Fig. 4. E¡ect of isoproterenol on AMPK. Adipocytes were incu-
bated for 10 min in the presence of 1 WM isoproterenol (Iso), 83
nM insulin (Ins), 0.5 M sorbitol (Hyp), 0.5 mM arsenite (Ars), 2
mM cpt-cAMP (cpt) or 2 mM AICAR prior to snap freezing. A:
The activity of AMPK was determined as outlined in Section 2 in
the presence of 200 WM AMP. Results shown are means þ S.E.M. of
the number of separate cell preparations shown. B: Cells were incu-
bated for 10 min in the presence of 1 WM isoproterenol (I), 2 mM
AICAR (A) or no further additions (C) prior to extraction and
measurement of p38 MAPK activity as described in Fig. 1.
Fig. 3. Dose response for the e¡ect of isoproterenol on p38 MAPK
activity. Adipocytes were incubated for 10 min in the presence of
the indicated concentrations of isoproterenol. Results are expressed
as percentage of the p38 MAPK activity in the absence of isoproter-
enol and are means þ S.E.M. of three separate cell preparations.
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Our results also show that isoproterenol gives rise to a
stimulation of AMPK in fat cells. This unexpected ¢nding
may be a result of ATP depletion that possibly occurs as a
result of stimulation of lipolysis by the L-adrenergic agonist
[30,31]. Direct e¡ects of isoproterenol, or related agonists, on
AMPK activity have not previously been reported. Treatment
of fat cells with AICAR has been shown to alter lipid metab-
olism, with AMPK activation inhibiting both lipogenesis and
isoproterenol stimulated lipolysis [19,20]. The e¡ects of
AMPK on lipolysis are thought to be brought about through
phosphorylation of Ser-565 of hormone-sensitive lipase, with
phosphorylation at this site preventing subsequent phospho-
rylation and activation of the lipase by cAMP-dependent pro-
tein kinase [32]. Our current ¢nding that isoproterenol stim-
ulates AMPK may represent a negative-feedback mechanism
to control lipolysis in response to L-adrenergic agonists. It
may also be involved in the inhibition of acetyl-CoA carbox-
ylase activity and hence lipogenesis. Isoproterenol was found
to inactivate acetyl-CoA carboxylase in fat cells primarily by
increasing the phosphorylation of Ser-79, the site phospho-
rylated by the AMPK, rather than by direct phosphorylation
of enzyme by cAMP-dependent protein kinase [33].
The activation of p38 MAPK by L-adrenergic agonists in
fat cells represents a novel mechanism for the regulation of
the p38 MAPK stress pathway, but the full physiological sig-
ni¢cance remains to be established. At present we cannot
eliminate the possibility that isoproterenol activates p38
MAPK through a decrease in cellular ATP content. However,
it is clear that the activation of p38 MAPK is not a direct
result of AMPK activation as AICAR, a potent activator of
AMPK, is without e¡ect on p38 MAPK.
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